Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMIR1K)

Drug Name
GSK184072 Drug Info
Synonyms
Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione
Indication
Disease Entry ICD 11 Status REF
Colon cancer 2B90.Z Discontinued in Phase 2 [1]
Hematologic tumour 2B33.Y Discontinued in Phase 2 [1]
Type-2 diabetes 5A11 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
6443207
CAS Number
CAS 162666-34-4
TTD Drug ID
DMMIR1K

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting NAD-dependent deacetylase sirtuin-1 (SIRT1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Resveratrol DM3RWXL Giant cell arteritis 4A44.2 Phase 3 [4]
GSK2245840 DMG7YQL Chronic obstructive pulmonary disease CA22 Phase 2 [5]
SEN-196 DMLDBQ5 Huntington disease 8A01.10 Phase 2 [6]
MB-12066 DMRSN2C Obesity 5B81 Phase 2 [7]
SRT2379 DM7DAKX Type-2 diabetes 5A11 Phase 1 [8]
SRT3025 DMRAXFH Type-2 diabetes 5A11 Phase 1 [9]
PMID25435179-Compound-WO2012106509Salermide DMLAH39 N. A. N. A. Patented [4]
CAMBINOL DMW46GY Discovery agent N.A. Patented [10]
PMID25435179-Compound-WO2012106509CAY10602 DM2F1T0 N. A. N. A. Patented [4]
PMID25435179-Compound-WO2012106509Tenovin-6 DMBSOED N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting CAP-dependent endonuclease (CDE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
4-substituted 2,4-dioxobutanoic acids DMELGKY Discovery agent N.A. Investigative [11]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CAP-dependent endonuclease (CDE) TTTG60L NOUNIPROTAC Inhibitor [2]
NAD-dependent deacetylase sirtuin-1 (SIRT1) TTUF2HO SIR1_HUMAN Activator [3]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024569)
2 Synthesis of natural flutimide and analogous fully substituted pyrazine-2,6-diones, endonuclease inhibitors of influenza virus. J Org Chem. 2001 Aug 10;66(16):5504-16.
3 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
4 Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
5 Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol. 2014 Dec;1(12):1047-52.
6 Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen. 2011 Dec;16(10):1153-69.
7 Pharmacological activation of Sirt1 ameliorates polyglutamine-induced toxicity through the regulation of autophagy.PLoS One.2013 Jun 10;8(6):e64953.
8 SRT2379, a small-molecule SIRT1 activator, fails to reduce cytokine release in a human endotoxemia model. Critical Care 2013, 17(Suppl 4):P8.
9 The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391.
10 Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem. 2009 May 14;52(9):2673-82.
11 Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Antimicrob Agents Chemother. 1996 May;40(5):1304-7.